Companies: | 51,220 |
Products and Services: | 2,875 |
Articles and publications: | 31,355 (+2) |
Tenders & Vacancies: | 17 |
(April 24, 2021): Personalized medicine promises to resolve some of the key challenges in biomedical and pharmaceutical industries. Medical simulation and digital twin technology are driving innovative prognostics, personalized clinical management and patient-specific medical devices, implants and prosthetics.
The global market size of personalized medicine surpassed $59.16 billion in 2019 and expected to reach $141.33 billion by 2027. The medical simulation sector of that market is projected to reach USD 3.7 billion by 2025 from $1.9 billion in 2020, at a CAGR of 14.6%. Bio-CFD is the world’s first computational fluid dynamics (CFD) platform for medicine and life science applications. With a first-stage mission to transform medical simulation in the $45 billion cardiovascular device market, Bio-CFD developed a cloud-computing application to personalize neurovascular disease diagnosis and management. Its operational workflow is designed to grant neurophysiologists and neurosurgeons equal access to CFD simulation capabilities like fluid dynamics engineers. “NeuroCFD is the flagship application of Bio-CFD that is designed to serve neurovascular medicine” says Dr. Khalid Saqr, the founder and CEO of the US-based medtech startup. “Our proprietary workflow allows physiologists to run hundreds of patient-specific CFD simulations on the cloud with a single few-minutes setup routine.” Dr. Saqr continued.
Bio-CFD focuses on boosting CFD technology adaption and scalability in the medical and pharmaceutical industries. Two clinical trials are now in progress to demonstrate the clinical advantages of NeuroCFD and secure seamless FDA (SaMD) approval. The application is deployed on the cloud computing server of CFD FEA SERVICE SRL, Italy. “The innovative technology provided by Bio-CFD takes medical simulation to a new level where medical professionals are able to harness the power of CFD to directly serve patients” Says Dr. Ruggero Poletto, the general director of the Italy based cloud-computing provider who currently hosts NeuroCFD through a collaborative agreement with Bio-CFD.
For more information, please visit https://bio-cfd.com/
###